Jefferies Maintains Viatris(VTRS.US) With Buy Rating, Maintains Target Price $15
Viatris Analyst Ratings
Piper Sandler Maintains Viatris(VTRS.US) With Hold Rating, Raises Target Price to $14
Viatris Is Maintained at Underweight by Barclays
Viatris Analyst Ratings
Barclays Maintains Viatris(VTRS.US) With Sell Rating, Raises Target Price to $12
Barclays Maintains Viatris(VTRS.US) With Sell Rating, Maintains Target Price $11
Barclays Maintains Viatris(VTRS.US) With Sell Rating, Maintains Target Price $11
Jefferies Maintains Viatris(VTRS.US) With Buy Rating, Maintains Target Price $15
Piper Sandler Maintains Viatris(VTRS.US) With Hold Rating, Maintains Target Price $13
Organon Downgraded, Amneal Upgraded as J.P. Morgan Reviews Specialty Pharma
Piper Sandler Maintains Viatris(VTRS.US) With Hold Rating, Maintains Target Price $13
Viatris Analyst Ratings
Viatris Analyst Ratings
Piper Sandler Maintains Neutral on Viatris, Raises Price Target to $11
Viatris Analyst Ratings
B of A Securities Downgrades Viatris to Underperform, Announces $9 Price Target
Viatris Analyst Ratings
Piper Sandler Sticks to Their Hold Rating for Viatris (VTRS)
Barclays Downgrades Viatris to Underweight, Announces $11 Price Target